Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy
Current Oncology · 17.06.2026 · 33 (6) · 364
DOI: 10.3390/curroncol33060364 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 17.06.2026. Verfasst von Georgios Maravelis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Metropolitan Hospital, 18547 Piraeus, Greece. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite technological advances in radiation therapy (RT), improvements in locoregional control of locally advanced disease remain limited, indicating a plateau in RT effectiveness. It is becoming increasingly clear that RT occurs within a dynamic metabolic microenvironment that merges oncogenic activity with metabolic and immune interactions. This includes responses to oxidative stress, regulation of cell death and survival signals, energy metabolism, protein synthesis, autophagy of molecules and organelles, and ultimately, the anti-tumor immune response. Each tumor, regardless of its histology, maintains a unique molecular and microenvironmental identity that influences its response to RT. Furthermore, RT acts as a cellular stressor that activates responses in cancer and stromal cells, impacting clinical outcomes. The concept of Metabolism and Immunity Adaptive Radiotherapy (M.I.A.R) recognizes that RT success depends not only on radiation dose and distribution but mainly on key interventions that alter and influence the biological environment before, during, and after therapy. It highlights the importance of an initial diagnostic workup, which is achievable with current tools, to identify tumor-specific oncogenes, metabolic, and immune profiles. Within the context of M.I.A.R., effective RT requires tumor preconditioning combined with concurrent use of drugs, including metabolism-targeting agents, to increase tumor sensitivity to radiation. Post-RT metabolic and immune interventions are essential for complete tumor eradication. This involves combining existing oncogene-targeting therapies with available immune treatments, supported by low-toxicity modulating drugs/agents with demonstrated preclinical activity against specific molecular and microenvironmental features. Overall, while MIAR remains a theoretical approach, existing preclinical and recent clinical data, e.g., those exploiting tumor hypoxia and re-oxygenation status, or post-RT immunotherapy, strongly support further dedicated investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Metropolitan Hospital, 18547 Piraeus, Greece.
- Department of Radiotherapy and Oncology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- Department of Radiation Oncology, Medical School, University of Thessaly, 41334 Larisa, Greece.
ORCID-Profile: Pantelis Skarlos, Michael I Koukourakis
Zitieren
APA
Maravelis, G., Koukourakis, I. M., Skarlos, P., & Koukourakis, M. I. (2026). Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy. Current Oncology, 33(6), 364. https://doi.org/10.3390/curroncol33060364
Vancouver
Maravelis G, Koukourakis IM, Skarlos P, Koukourakis MI. Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy. Current Oncology. 2026;33(6):364. doi:10.3390/curroncol33060364
BibTeX
@article{Maravelis2026,
author = {Maravelis, Georgios and Koukourakis, Ioannis M and Skarlos, Pantelis and Koukourakis, Michael I},
title = {Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {6},
pages = {364},
doi = {10.3390/curroncol33060364}
}
EUVIMED